ReviewJournal of cellular and molecular medicine2025
SCENE: Signature Collection for Endometrial Cancer Prognosis.
Review in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Tool Comparison for Detecting Tumour Cells in Endometrial Cancer via Single-Cell Copy Number Variations Analysis.Journal of cellular and molecular medicine · 2025Article
- SCENE: Signature Collection for Endometrial Cancer Prognosis.Journal of cellular and molecular medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endometrial cancer (EC) is the most common malignancy of the female reproductive tract; its prognosis is difficult to predict. Despite the technique of single-cell transcriptomic analysis (scRNA-seq) returning single-cell level expression data and promising to improve the accuracy of prognosis prediction, a tool that correlates transcriptomic signatures with survival is missing. To this aim, we have created SCENE, a database that collects information to correlate EC transcriptomic signatures with patient prognosis. We performed a review of the literature present in PubMed to collect transcriptomic signatures annotated with their characteristics, differential expression between healthy and sick patients, between patients with more and less favourable prognosis, and cellular pathways in which the genes are involved, as well as references to the original studies. The analysis of about 200 studies has allowed us to obtain 700 mRNA signatures, 60 microRNA (miRNA), and 150 long non-coding RNA (lncRNA), involved in 60 molecular pathways. Each signature is annotated with its specific prognostic outcome that it influences, such as overall survival (OS), progression-free survival (PFS), relapse-free survival (RFS), and disease-specific survival (DSS). The SCENE resource collects and annotates information that is widespread in the literature to facilitate the interpretation of transcriptomic data obtained with any technique in EC. In the case of scRNA-seq data, SCENE may reveal cells predisposed to develop therapy resistance and metastasis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.